Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Opendoor Technologies Inc (OPEN) vs BIO-TECHNE Corp (TECH) Price & Performance

Opendoor Technologies IncTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Opendoor Technologies Inc vs BIO-TECHNE Corp — how do they compare? Opendoor Technologies Inc trades at $2.32 (market cap $2.22B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 5.1× Opendoor Technologies Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Opendoor Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Opendoor Technologies Inc for 33 Days and BIO-TECHNE Corp for 63 Days on average.

OPENTECH
Market Cap
$2.22B$11.36B
Volume
28,705,8925,390,331
Sector
Real EstateHealth
52-Week High
$9.37$72.61
52-Week Low
$2.27$43.31
Typical Hold Time
33 Days63 Days
Enterprise Value
$3.29B$11.39B
Dividend Yield
—0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Opendoor Technologies Inc

Opendoor Technologies (OPEN) trades at $2.27 with no recent price movement, reflecting ongoing investor caution. The stock shows bearish technical signals with most moving averages and oscillators indicating selling pressure. Fundamentally, the company continues to struggle with profitability, posting a -46.74% net income margin and -$1.30B net loss in 2025 despite $4.37B revenue. Recent news highlights the company's mortgage expansion strategy and ongoing challenges in the housing market.

While analyst consensus suggests significant upside potential with a $4.92 price target, the company faces substantial execution risks amid persistent losses and high debt levels. The path to profitability remains uncertain, with revenue declining from $15.6B in 2022 to $4.4B in 2025. Investors should weigh the discounted valuation against ongoing operational challenges in the volatile housing sector.

BIO-TECHNE Corp

TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.

The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

OPEN
20% Buy80% Sell
Avg holding period · 33 Days
TECH

No sentiment data available yet.

Top news

Latest headlines on both assets

About Opendoor Technologies Inc

Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.

Read more on OPEN →

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH →